who api prequalification and apimf procedure · who api prequalification and apimf procedure antony...
TRANSCRIPT
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
WHO API prequalification and APIMF procedure
Antony Fake PhDWHO Medicines Prequalification Programme
1
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Overview
APIMF Procedure
API PQ Procedure
API-related changes – Amendments & Variations
Documentation requirements
Common deficiencies
3
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Abbreviations
• API – Active Pharmaceutical Ingredient
• FPP – Finished Pharmaceutical Product
• API PQ – API Prequalification
• APIMF – Active Pharmaceutical Ingredient Master File (DMF)
• CPQ – Confirmation of API PQ Document
• SRA – Stringent Regulatory Authority
• GMP – Good Manufacturing Practice
• PQP – Prequalification of Medicines Programme
WHO API prequalification and APIMF procedure tutorialMumbai, September 20125
APIMF Information
API
FPP
S & E
+
+
An application to prequalify an FPP typically has three parts:
Information on the preparation and control of the API.
Information on the preparation and control of the FPP.
Safety and efficacy data, e.g. commonlya bioequivalence study.
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
API
FPP
S & E
or or
+
+
There are 4 ways to submit API information for a FPP.
APIMFProcedureAPI-PQ CEP Full
dossieror
APIMF Information
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Two uses of APIMFs in PQP
APIMFsAPIMF
ProcedureAPI
Prequalification
APIMFs are used to support FPP Prequalification and API prequalification.
7
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
APIMF Procedure
+
+
FPP Manufacturer
API Manufacturer
APIMF assessment is conducted in conjunction with an FPP application
AP
RP
9
WHO API prequalification and APIMF procedure tutorialMumbai, September 201210
The APIMF Procedure• This procedure is only used to support the evaluation of FPP
prequalification applications.
• Active since March 2008.
• It is inspired by the Active substance master file (ASMF) procedure in the EU.
• Most APIMF evaluations occur at bimonthly assessment meetings held in Copenhagen.
• The use of APIMFs in the PQ programme is described in Technical Report Series 948 (TRS948).
WHO API prequalification and APIMF procedure tutorialMumbai, September 201211
The APIMF Procedure
APIMF holder FPP applicant
APIMF submission to APIMF focal point
FPPsubmission
APIMF assessment
APIMF acceptance FPP assessment
FPP prequalification
Letter of Access
WHO API prequalification and APIMF procedure tutorialMumbai, September 201212
APIMF holder responsibilities
• To submit the latest APIMF version to the WHO.
• To provide the WHO PQ with letters of access.
• To respond and resolve questions from the APIMF assessment.
• To inform the APIMF focal point of all changes, updates, amendments, new versions.
• To inform associated FPP applicants of all changes stipulated in the APIMF amendment letter.
WHO API prequalification and APIMF procedure tutorialMumbai, September 201213
FPP Applicant responsibilities
• To submit the open part of the APIMF and Letter of Access as part of the FPP application.
• To submit minor or major API-related variations to the WHO as required.
• To ensure such variations are approved before these changes are adopted in the preparation or control of the FPP.
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Advantages of the APIMF Procedure
• It allows the submission of confidential information by the API manufacturer without disclosure to the FPP applicant.
• One APIMF may be used to support multiple FPP applications without the need for repeated evaluations.
• It is applicable to both pharmacopoeial and non-pharmacopoeialAPIs.
• FPPs supported by an APIMF have reduced variation requirements (see draft variation guidance).
• The APIMF holder prepares and maintains the APIMF information and answers all queries directly.
14
WHO API prequalification and APIMF procedure tutorialMumbai, September 201215
Statistics
Sept 2012April 2012April 2011
164 APIMFs155 APIMFs112 APIMFsTotal number of active APIMFs
94 APIMFs85 APIMFs48 APIMFsAccepted
52 APIMFs38 APIMFs58 APIMFsIn progress
18 APIMFs28 APIMFs10 APIMFsQueued for assessment
All APIMFs active in PQP
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Choosing your API supplier
Manufacturer with APIMF and GMP compliance – API Prequalification
Manufacturer withan APIMF, or CEPavailable
Manufacturer without APIMF available
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
What is API Prequalification?
API Manufacturer
API Prequalification
It is a scheme for API manufacturers only
There is no involvement by FPP manufacturers
18
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
What is API Prequalification?
• It is a scheme for manufacturers of APIs that are used in medicinal products for HIV, TB, Reproductive Health and Malaria.
• It seeks to verify and identify APIs that are of good quality and manufactured in compliance with GMP.
• It commenced as a pilot project in October 2010.
• It is part of the Prequalification of Medicines Programme, WHO based in Geneva.
19
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Prequalification of Medicines website
http://www.who.int/prequal
20
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Benefits to API manufacturers
• Recognition as a source of quality API, manufactured in compliance with GMP.
• Serves as a point of difference between good quality and poor quality APIs.
• Opportunities to verify compliance with GMP.
• Opportunities to compile, revise and refine their regulatory documentation, leading to quicker acceptance by other national regulatory agencies.
• There is no fee.
21
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Invitation
Application
Assessment(GMP)
Assessment(Quality)
Decision
Publishing
How are APIs Prequalified
22
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
3rd Invitation for EOI
Invited Active Pharmaceutical IngredientTherapeutic area
Abacavir, Atazanavir, Darunavir, Didanosine, Efavirenz, Emtricitabine, Etravirine, Lamivudine, Lopinavir, Nevirapine, Raltegravir, Ritonavir, Stavudine, Tenofovir, Zidovudine
HIV
Amodiaquine, Artemether, Artesunate, Dihydroartemisinin, Lumefantrine, Mefloquine, Piperaquine, Pyrimethamine, Sulfadoxine, Pyronaridine
Anti-malarial
Amikacin, Capreomycin, Cycloserine, Ethambutol, Ethionamide, Isoniazid, Kanamycin, Levofloxacin, Moxifloxacin, Ofloxacin, Para-Aminosalicylic Acid (PAS), Prothionamide, Pyrazinamide, Rifampicin, Streptomycin, Terizidone
Anti-tuberculosis
Desogestrel, Estradiol, Ethinylestradiol, Etonogestrel, Levonorgestrel, Medroxyprogesterone, Mifepristone, Misoprostol, Norethisterone, Norgestrel, Oxytocin
Reproductive health
Diethylcarbamazine, Mebendazole Neglected Tropical Diseases
23
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Invitation
Application
Assessment(GMP)
Assessment(Quality)
Decision
Publishing
Application
24
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Application
• An application for API Prequalification is made by the API manufacturer, or agent.
• An applicant does not need to be supplying API to a WHO Prequalified FPP to seek API prequalification.
25
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Application
• The PQ application form.
• An APIMF (if not previously provided).
• A Site Master File (if not previously provided).
• Any further evidence of GMP at the facility (optional).
An application should consist of:
26
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
The APIMF in paper and CD version should be sent to Copenhagen
Only the CD version should be sent to Geneva
Application
27
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Invitation
Application
Assessment(GMP)
Assessment(Quality)
Decision
Publishing
Assessment – Quality (APIMF)
28
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
APIMF submission
There are four options for APIMFs when seeking PQ.
Read the application form closely.
Option 4 allows referral to an existing APIMF already submitted for the APIMF procedure.
Remember the existing APIMF must meet all current requirements.
It might be a good time to submit a revised/updated APIMF.
29
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
APIMF - Technical content
Excellent technical guidance can be found in the module 3.2.S sections (pages 11 to 31) of the recently published guideline :
Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part.
http://www.who.int/prequal/info_general/documents/generic_guide/GenericGuideline_Quality.pdf
30
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Assessment - GMP
Invitation
Application
Assessment(GMP)
Assessment(Quality)
Decision
Publishing
31
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Assessment – GMP
• By providing evidence of current compliance:
– GMP certificates, inspection reports, CAPAs, the most recently completed Product Quality Review (PQR) report.
or
• By inspection by the WHO.
There are two ways to demonstrate GMP compliance at the API manufacturing facility.
32
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Assessment – GMP
• Inspections performed previously by WHO, a member of PIC/S, or an SRA.
• Inspection must have occurred within 3 years of application.
• Inspections must be API specific.
Assessment of GMP compliance at the site of API manufacture takes into account:
The WHO will perform an inspection if, after assessment and requests for information, GMP compliance can not be established.
33
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Assessment of GMP
An SRA is a medicines regulatory authority in a country that is:
• a member of the ICH: Japan, USA, EU member; or
• an ICH Observer, e.g. Swissmedic, Health Canada; or
• associated with an ICH member through a legally binding mutual recognition agreement, e.g. Australia, Iceland, Liechtenstein, Norway…etc.
34
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
WHO GMP Certificates• There are many certificates circulating that appear to be issued by the
WHO, but they are not.
• Certificates might be issued in the WHO format, or the inspection may have occurred against WHO criteria, but this is not a WHO inspection.
• Successful inspections conducted by the WHO are published in WHOPIR that can be found at this link:
http://www.who.int/prequal/WHOPIR/pq_whopir.htm
There is no such thing. The WHO does not issue GMP Certificates.
35
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Decision
Invitation
Application
Assessment(GMP)
Assessment(Quality)
Decision
Publishing
36
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Decision
• Once the APIMF is accepted the applicant will received an Letter of APIMF acceptance. This is not prequalification.
• A final conclusion over GMP status may still be required if this has not been achieved already.
• Once both the APIMF and GMP us accepted the application is considered for sign-off.
• The applicant will be contacted by WHO to confirm final details for publishing. Expressions of storage statement may differ to meet WHO requirements.
37
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Publishing
Invitation
Application
Assessment(GMP)
Assessment(Quality)
Decision
Publishing
38
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Publishing
List of PQ APIsWebsite (Public)
Confirmation Document (Private)
+ WHOPIRsWebsite (Public)
39
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
WHO List of Prequalified APIs
• WHO application number.• INN name.• Date of prequalification.• Name of the applicant• Sites of API manufacture.• The APIMF version number.• The API specification version
number.
• The primary and secondary packaging components.
• The assigned re-test period.
• The recommended storage conditions.
• Confirmation of API PQ document issue date
Intended for: UN agencies, National medicine authorities, FPP manufacturers, public
Publically available
40
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Confirmation of API PQ document
• The assigned WHO application number.
• The INN name of the active pharmaceutical ingredient.
• API manufacturer company name.
• The API specification version number.
• A copy of the API specifications.
• The assigned re-test period.
• The recommended storage conditions.
• A copy of the assay and related substances test methods.
discretiontheirProvided to the API manufacturer for distribution at
Intended for: UN agencies, National medicine authorities, FPP manufacturers
41
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Confirmation of API PQ document (CPQ)
It is intended that the CPQ is circulated to relevant parties.
FPP manufacturer’s can submit the CPQ and withdraw from the APIMF procedure.
This will have post-Prequalification benefits in terms of the number of variations they will need to file.
42
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
API Prequalification Performance
• There is very positive feedback from FPP manufacturers whenever PQ of APIs is discussed.
• Applications and the number of prequalified APIs continues to increase.
1 Sept 20121 November 20111 April 2011
62298Total number of applications
1852Number of PQ APIs
43
WHO API prequalification and APIMF procedure tutorialMumbai, September 201244
API Related Changes
Amendments and Variations
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
API-related changes
API manufacturers who have submitted an APIMF in support of:
•their own Prequalified API, or
•the prequalification of an associated FPP
Have obligations to maintain their APIMF with accurate information.
And
To seek approval for any API related changes (APIMF amendment)
45
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
API-related changes
Since the FPP manufacturer is responsible for all changes to theFPP, this includes API details.
Therefore:
Associated FPP manufacturers participating in the PQ also have to obtain approval for the API-related change.
46
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
API-related changes
Currently, this means
1.The submission of an APIMF amendment to PQP for all API changes.
2.Receipt of the amendment acceptance letter for all API changes.
3.Passing of the letter to any associated FPP manufacturers.
4.The submission of an API-related variation by FPP manufacturers for all API changes.
47
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
API Manufacturer
APIMF Amendment
PQP
Acceptance
Notification to FPP manufacturer
API-related Variation
Acceptance
API-related change Process
48
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Draft guidance on Variations to Prequalified FPP have been circulated. Guidance on Amendments to APIMFs is about to be circulated.
Both guidance documents have:
•A risk-based approach to changes.
•Rely upon manufacturer self-assessment of many changes.
•Detailed information on required supporting documents.
•Identical technical requirements.
API-related changes
49
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
The fundamental responsibilities of API and FPP manufacturers remain the same, but the revised guidance documents
•Offer a reduction in the burden upon both PQP and manufacturers.
•Recognition of API manufacturers using the APIMF procedures.
•Recognition of API manufacturers using a PQ’d API.
API-related changes
50
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
New APIMF Amendment Guidance
Four types of changes classes are envisaged
•Annual Amendment Notifications (AAN)
•Immediate Amendment Notifications (IAN)
•Minor Amendment (Amin)
•Major Amendment (Amaj)
51
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Annual Amendment Notifications (AAN)
APIMF holders must satisfy themselves that they meet all of the prescribed conditions for the change.
ANs and the associated documentation should be submitted to WHO PQP within 12 months of implementation of the change.
APIMF holders may group several AN changes as a single submission, or coincide these notifications with the submission of an updated APIMF, or other amendment types.
52
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Immediate Amendment Notifications (IAN)
APIMF holders must satisfy themselves that they meet all of the prescribed conditions.
APIMF holders must submit all required documentation with the notification application.
A change can be implemented immediately at the time of submission.
The change can be considered accepted if an objection is not issued by WHO PQP within 30 calendar days of the date of acknowledgement of receipt of the application.
53
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Minor amendment (Amin)
APIMF holders must satisfy themselves that they meet all of the prescribed conditions for the change and submit all required documentation with the amendment application.
A minor amendments can be implemented if no objection letter hasbeen issued within a time period indicated on the WHO PQP website.
Should questions arise during the specified period, the change can only be implemented on receipt of a letter of acceptance from WHO PQP.
A target assessment time will be published.
54
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Major Amendment (Amaj)
The documentation required for the change included in this reporting type should be submitted as a minimum.
Prior acceptance by WHO PQP is required before the change can beimplemented.
A letter of acceptance will be issued for all major amendments once the amendment is considered acceptable.
55
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
APIMF Amendment Process
Three phases
1.Screening
2.Audit or Assessment
3.Implementation or Acceptance
56
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Amendment application
Screening Rejection email
Accepted for assessment
Annual notifications &Immediate notification
Minor AmendmentsMajor amendments
Acknowledgment email
Risk‐basedAudit process
AssessmentAssessment
Issues arising?
Notification acceptable by default Notification not acceptable by default Amendment acceptable after 30 days be default
No further action No further action
Issues arising? Issues arising?
Letter of refusalAcceptance letter
Assessment
Rejection
An email will be sent to the applicant
57
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Amendment application
Screening Rejection email
Accepted for assessment
Annual notifications &Immediate notification
Minor AmendmentsMajor amendments
Acknowledgment email
Risk‐basedAudit process
AssessmentAssessment
Issues arising?
Notification acceptable by default Notification not acceptable by default Amendment acceptable after 30 days be default
No further action No further action
Issues arising? Issues arising?
Letter of refusalAcceptance letter
Assessment
Rejection
Notifications are accepted by default
58
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Amendment application
Screening Rejection email
Accepted for assessment
Annual notifications &Immediate notification
Minor AmendmentsMajor amendments
Acknowledgment email
Risk‐basedAudit process
AssessmentAssessment
Issues arising?
Notification acceptable by default Notification not acceptable by default Amendment acceptable after 30 days be default
No further action No further action
Issues arising? Issues arising?
Letter of refusalAcceptance letter
Assessment
Rejection
Notifications will be audited rather than
assessed.
59
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Amendment application
Screening Rejection email
Accepted for assessment
Annual notifications &Immediate notification
Minor AmendmentsMajor amendments
Acknowledgment email
Risk‐basedAudit process
AssessmentAssessment
Issues arising?
Notification acceptable by default Notification not acceptable by default Amendment acceptable after 30 days be default
No further action No further action
Issues arising? Issues arising?
Letter of refusalAcceptance letter
Assessment
Rejection
This could lead to questions and
potentially the reversal of the change
60
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Amendment application
Screening Rejection email
Accepted for assessment
Annual notifications &Immediate notification
Minor AmendmentsMajor amendments
Acknowledgment email
Risk‐basedAudit process
AssessmentAssessment
Issues arising?
Notification acceptable by default Notification not acceptable by default Amendment acceptable after 30 days be default
No further action No further action
Issues arising? Issues arising?
Letter of refusalAcceptance letter
Assessment
Rejection
Minor Amendments are acceptable 30 days after
acknowledgment
61
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Amendment application
Screening Rejection email
Accepted for assessment
Annual notifications &Immediate notification
Minor AmendmentsMajor amendments
Acknowledgment email
Risk‐basedAudit process
AssessmentAssessment
Issues arising?
Notification acceptable by default Notification not acceptable by default Amendment acceptable after 30 days be default
No further action No further action
Issues arising? Issues arising?
Letter of refusalAcceptance letter
Assessment
Rejection
If there are no objections, no further correspondence
will be received
62
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Amendment application
Screening Rejection email
Accepted for assessment
Annual notifications &Immediate notification
Minor AmendmentsMajor amendments
Acknowledgment email
Risk‐basedAudit process
AssessmentAssessment
Issues arising?
Notification acceptable by default Notification not acceptable by default Amendment acceptable after 30 days be default
No further action No further action
Issues arising? Issues arising?
Letter of refusalAcceptance letter
Assessment
Rejection
If there are questions then assessment follows the
major amendment process and implementation can
only occur after receipt of the acceptance letter
63
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
APIMF Amendment Process
The success of the amendment process relies on three things:
1.Correct assessment of the change type by applicants
2.Correct submission of supporting documentation
3.Correct submission of replacement sections
If all three do not occur the assessment burden will remain.
Consequently, in order not to disadvantage others these requirements must be strictly enforced. Applications will be rejected.
64
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Correct assessment of the change also relates to conditions and documentation
65
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
APIMF Amendment Process
The success of the amendment process relies on three things
1.Correct assessment of the change type by applicants
2.Correct submission of supporting documentation
3.Correct submission of replacement sections
If all three do not occur the assessment burden will remain.
Consequently, in order not to disadvantage others these requirements must be strictly enforced. Applications will be rejected.
66
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
For each amendment supporting data will be specified – minimum data
67
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
APIMF Amendment Process
The success of the amendment process relies on three things
1.Correct assessment of the change type by applicants
2.Correct submission of supporting documentation
3.Correct submission of replacement sections
If all three do not occur the assessment burden will remain.
Consequently, in order not to disadvantage others these requirements must be strictly enforced. Applications will be rejected.
68
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Replacement sections for the APIMF are critical to ensure accurate documentation. Even if a small changes are made replacement sections are required. An updated APIMF would also be acceptable.
69
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Several amendments can be grouped together especiallyAnnual amendments and other amendments.
If multiple amendments are grouped, then the change category of the most significant change will be applied to the application.
Don’t forget about consequential changes. These are not indicated in either guidance because there are too many scenarios.
API Amendments and variations
70
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
API-related changes: Variations
The variation guidance:
•Also incorporates risk based assessment.
•Recognition of API manufacturers using the APIMF procedures
•Recognition of API manufacturers using a PQ’d API
71
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Risk based organization of change types
For example:
Requires assessmentSelf assessable
72
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Introduction of “self assessable” changesChange category
Description
Annual notification
May be implemented immediately.Have 12 months to lodge application.Documentation must be held but need not be submitted.
Immediate notification
May be implemented upon submission of application.30 day window for PQP objection.Documentation must be provided.
Minor variation Change may be implemented if no objection is raised X days after acknowledgement.Documentation must be provided.
Major variation Change may not be implemented until an acceptance letter is received.Documentation must be provided.
73
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Recognition of the APIMF procedure
74
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Recognition of the APIMF procedure
75
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Recognition of the use of PQ’d APIs
A variation is only required if there is a change to the CPQ
76
WHO API prequalification and APIMF procedure tutorialMumbai, September 201277
APIMF DocumentationRequirements
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
APIMF Documentation
The submitted APIMF, or amendment should:
•be prepared in CTD format
•be separated into open (applicant) and closed (restricted) sections
•be paginated throughout the entire document. Restarting page numbers for each subsection section is not permitted
•include a contents page with page number references to each of the CTD subsections
•be assigned a manufacturer's version number that should be present in the footer or header of each page of the APIMF.
78
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
The electronic version of the APIMF should also meet:
•Separate files should be provided for the open and closed sections.
•Single files should not exceed 30MB in size. File path-length should not be excessive.
•The document should be provided in text-selectable PDF format. Document bookmarks for each of the CTD subsections should be added for each of the CTD subsections. In additional the use of hyperlinks within the body of the text is encouraged.
•A scanned copy of the paper version will not be accepted. The inclusion of scanned copies of supporting documents such as Certificates of Analysis, authorized specifications, signed protocols, etc are permitted.
APIMF Documentation
79
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
APIMF version numbers
Each APIMF should be assigned a unique version number.
FPP manufacturers and PQP should hold APIMFs with the same version numbers.
Amendments should be numbered to reflect the “parent” APIMF version they below to. Whereas an updated APIMF should be given a new version number.
80
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Document submitted APIMF version
Initial APIMF Lamiv/AP00/May-2012Lamiv/RP00/May-2012
Lamiv/AP00/May-2012Lamiv/RP00/May-2012
Amendment Lamiv/AP00/May-2012/Amend 3.2.S.7 Lamiv/AP00/May-2012Lamiv/RP00/May-2012Lamiv/AP00/May-2012/Amend 3.2.S.7
Revised APIMF Lamiv/AP01/Dec-2012Lamiv/RP00/May-2012
Lamiv/AP01/Dec-2012Lamiv/RP00/May-2012
APIMF version numbers
81
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Presentation of your APIMF
An APIMF, like a house, should be built on good foundations. These are scientific data and manufacture.
83
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Presentation of your APIMF
But! If it is not presented well no one is going to buy it.
84
WHO API prequalification and APIMF procedure tutorialMumbai, September 201285
Common requirements
1. Numbers and traceability
• Make sure to include method numbers, specification numbers, batch numbers, method validation report numbers, etc.
• Any document numbers that would help a GMP auditor to verify documents when they visit.
There are common issues that should be considered for all sections of your APIMF.
WHO API prequalification and APIMF procedure tutorialMumbai, September 201286
Common requirements
2. State the obvious
It might be obvious to you, but it may not be to the reviewer.
For every CTD subsection there are a number of issues addressed in guidance. Not all will be applicable. If they are not applicable, say so.
e.g. If the manufacturing process does not use recovered solvents, include a sentence saying:
"No recovered solvents are used in the manufacturing process."
WHO API prequalification and APIMF procedure tutorialMumbai, September 201287
Common requirements
Data Summarised information Discussion
For example: Chromatograms, method
validation reports, spectra, signed API specifications, etc
For example: API physical properties,
impurities tables, specifications, stability
data, etc
For example: Explanations, justifications for
limits, reasoning for impurities, stability conclusions, etc
As appendices Main part of the APIMF Main part of the APIMF
Normally included Normally included Often missing
Necessary Important Essential
3. Discussion – An APIMF contains three types of information
WHO API prequalification and APIMF procedure tutorialMumbai, September 201288
Common requirements
3. Discussion
Whenever a section of the guideline uses words like discuss, compare, justify…etc, it is expected that the limit, specifications, conclusion or decision are explained.
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Starting material quality
• Polymorphism
• Specifications
• Stability deficiencies
• Impurities
Frequent API Issues
89
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Traditional manufacturing
Rawmaterials Final API
Traditionally, the API manufacturer manufactured the API from simple raw materials at their own facility.
This meant it was safe to assume that the molecule used in the first step at the API manufacturer's factory was an appropriate API-SM.
90
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Raw Material Final API
API-SM
API-SMIntermediate
Increasingly, intermediates late in the synthesis are being purchased.
This means the API-SM can not be assumed to be the molecule used in the first step at the API manufacturer's factory.
91
Contemporary manufacturing
WHO API prequalification and APIMF procedure tutorialMumbai, September 201292
API Starting Material
It does not matter if you only manufacture the last step in the process. Information on preparation of the API is required commencing from simple molecules (API stating material for synthesis).
N
NH
N N
OCH3
N
NH
N
O CH3
ClNH
Final APIToo complex to be API-SM
(1)(2)
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
The information on API SM preparation is not sufficiently detailed or is missing.
•Information on the API SM preparation is needed to determine theappropriateness of the specifications.
•Detailed information is usually not required, because the SM should be relatively simple.
•This information is often supplied in form of a flow-chart (synthetic transformation, reagents, and solvents).
•If there are two or more suppliers of the API SM, information on the preparation of the SM from each supplier should be provided.
API Starting Material
93
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Information on the API SM manufacturer is missing
•For each SM supplier, the name and manufacturing site address of the manufacturer should be indicated.
•If there are several manufacturers, it should be clarified whether the SM obtained from different sources is prepared by the same route ofsynthesis or if different routes are used.
API Starting Material
94
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
The API SM specification is not satisfactory.
•The specifications should include: an ID test, assay test and limits, specified, unspecified and total impurities limits.
•The limits should be justified by the demonstrated ability to manufacture API from batches of SM with similar impurity levels.
•Each API SM supplier does not have to have the same specifications but a single SM specifications should be defined by the API manufacturer and applied to all sources of SM.
•The carry-over of impurities into the final API should be considered and discussed. The same applies for solvents, reagents, and catalysts used in the SM preparation, as needed.
API Starting Material
95
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Possible scenario
N
NH
N N
OCH3
N
NH
N
O CH3
ClNHN
NH
N
O CH3
ClClN Cl
Cl
O
N
CH3
NH2
Cl
+
NevirapineFinal intermediateAPI-SM
Detailed in appendices for each API-SM supplier
Detailed in main text ofsection 3.2.3.2
(1)(2)(3)(5) (4)
Starting material
96
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
API polymorphism
• Polymorphic forms may possess different chemical and physical properties, that can have a direct impact FPP properties, such as stability, dissolution and bioavailability.
• Unexpected appearance or disappearance of a polymorphic form may lead to serious pharmaceutical consequences.
• We need to know what polymorph is consistently produced and if it is stable.
97
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Polymorphism known Polymorphism not known
Highly soluble API
The polymorphic form produced should be assigned.
The crystalline form produced should be determined.
Non-highly soluble API
The polymorphic form produced should be assigned. Stability of the form should be determined
The crystalline form produced should be assigned. Crystallinity under different crystallisation condition should be investigated.Stability of the form should be determined
API polymorphism
98
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• It is important that the manufacturer provides a signed, dated and version-numbered specification. This is to ensure traceability of testing requirements in case of GMP audits and future variations.
• This may be a scanned copy as an appendix in addition to a tabulated version in the body of the APIMF.
• The API specifications should also include reference to analytical procedures and whether they are compendial or not (i.e. pharmacopoeial reference or in-house reference).
• Regardless of pharmacopoeial requirements, PQP expects a test for heavy metals to be included and a test for any unknown (0.10%)
API Specifications
99
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Cross-validation data are not submitted when in-house methods are used for controlling pharmacopoeial APIs
If an officially recognized compendial standard is claimed and an in-house method is used (e.g. for assay or for specified impurities), equivalence of the in-house and compendial methods should be demonstrated.
Duplicate analyses of one sample by both methods or by spiking the API with impurities at concentrations equivalent to their specification limits.
API Specifications
100
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
PQP requires that a retest period and storage condition is assigned to an API.
Unlike some jurisdictions, notably Europe, the absence of a storage statement is not permitted.
PQP requires that this information is clearly stated in section 3.2.7.1 of the APIMF and clearly stated on the label.
101
Stability
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
PQP has specific storage statements that should be adhered to:
•Do not store above 25 C
•Do not store above 30 C
•Store in a refrigerator (2 C to 8 C)
•Store in freezer
102
Stability
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012103
“Protect from moisture” can be used when long-term trials at 30ºC were performed at the lower humidity (65%RH), or where there areknown concerns regarding the API.
“Protect from light” should be used when the API is known to be photosensitive, or where photo stability is unknown, i.e. no pharmacopoeial statement and no photo stability trials were submitted.
Stability
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Words of a similar meaning can be used, for instance:
“Do not store above 25ºC” ≈ “Store below 25ºC”
But not
“Do not store above 25ºC” ≈ “Store 15ºC ± 10ºC”
Or the use of non-specific terms such as
“Store at room temperature”
104
Stability
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
If there is no data available at 30ºC then the API manufacturer is requested to commit to initiating long-term stability trials at 30ºC and to change the recommended storage conditions to stored below 30ºC once 24 months data has been accumulated.
If the API is known to be unstable at 30ºC then data is expected at 25ºC.
If there have been corrections or revision to the retest period and storage condition, this information must be incorporated in future revised APIMF versions.
105
Stability
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
ImpuritiesQuestion:
If a manufacturer controls impurity content in accordance with apharmacopoeial monograph can we accept the specifications?
106
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Question:
If a manufacturer controls impurity content in accordance with apharmacopoeial monograph can we accept the specifications?
Unfortunately no, monographs are developed based upon how the API was prepared historically.
A particular manufacturer's manufacturing method may lead to unexpected impurities, due to a different route of synthesis, different reagents, etc.
Impurities
107
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Setting an impurity limit
1.What are the potential impurities?
2.What impurities actually occur?
3.When to specify impurities.
4.Setting limits for impurities.
Impurities
108
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
All potential impurities
Observed impurities
Impurities needing to becontrolled in specifications
Impurities withindividual limits
109
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
What are the potential impurities?
• The first step in setting impurity specifications is to consider what potential impurities might be present, based upon all available information.
• This step is often poorly performed by applicants.
• There is a tendency to skip this step in discussions and just adopt pharmacopoeial specifications if a monograph exists.
110
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
What are the potential impurities?
• Impurities introduced during manufacture
• API degradation products
• API reaction by-products
Impurities can be divided into:
111
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
API SM
Reactionintermediate
Final API
ReagentsSolventsCatalysts
Degradation
By-products
By-products
SMimpurities
ReagentsSolventsCatalysts
Potential Impurities
Residue of the SMResidue of the intermediateImpurities in the SMReagentsSolventsCatalystsReaction by-productsDegradation products
What are the potential impurities?
112
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
What are the potential impurities?
What are the possible reaction by-products?
• Here some chemistry knowledge would be helpful.
Advice:
• Look for areas of functionality, particularly C-O, C-N, and double bonds.
• Consider all the impurities specified in relevant pharmacopoeialmonographs.
113
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
What are the potential impurities?
What are the potential degradation impurities?
•Pharmacopoeial monograph transparencies.
•Forced degradation studies.
114
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
What impurities actually occur?
Observed impurities
Impurities needing to becontrolled in specifications
Impurities withindividual limits
115
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012116116
What impurities actually occur?
Potential impurities can be excluded by either testing the final API or FPP, or a relevant proceeding molecule.
Some pharmacopoeial impurities may not be present if a differentmanner of preparation,( reagents, synthesis) is used.
For degradants, look to long-term stability data. The presence of an impurity under accelerated conditions does not mean it will appear under long-term conditions.
Investigation of batch analysis and long-term stability data.
Impurities present at levels greater than the ICH reporting threshold should be reported by the manufacturer.
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
What impurities actually occur?
Analytical methods
• If you are looking for an impurity using a test method that can not detect the impurity then you are wasting your time.
• It is important for the manufacturer to detail the methods used.This is often not clear in submitted dossiers if different test methods have been used at different times.
• Full validation of investigative method is unnecessary. Demonstrated specificity and appropriate LOD/LOQs are important, especially for genotoxins.
117
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
When to specify impurities
Impurities needing to becontrolled in specifications
Impurities withindividual limits
118
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012119
When to specify impurities
Organic impurities
• Any impurity routinely observed in batch data or long-term stability trials should be controlled by the impurity specifications.
• Impurities observed below the ICH identification threshold need not be individually specified in the specifications. They can be controlled under the limit for any unspecified impurity.
• Impurities above the ICH identification threshold need to be identified and individually specified in the specifications.
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
When to specify impurities
• Drug 1 – ICH ID Threshold = 0.10%, or 1.0mg
• Maximum daily dose 20 mg
• Peak observed in batch data on average ~0.12%, should it be specified in the specifications?
120
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
When to specify impurities
• Drug 1 – ICH ID Threshold = 0.10%, or 1.0mg.
• Maximum daily dose 20 mg.
• Peak observed in batch data on average ~0.12%, should it be specified in the specifications?
• Yes
121
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
When to specify impurities
• Drug 1 – ICH ID Threshold = 0.10%, or 1.0mg
• Maximum daily dose 20 mg
• Peak observed in batch data on average ~0.12%, should it be specified in the specifications?
• Yes
• Should it be identified?
122
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
When to specify impurities
• Drug 1 – ICH ID Threshold = 0.10%, or 1.0mg
• Maximum daily dose 20 mg
• Peak observed in batch data on average ~0.12%, should it be specified in the specifications?
• Yes
• Should it be identified?
• Yes
123
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Setting limits for impurities
Impurities withindividual limits
124
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012125
Setting limits for impurities
• The limits must be qualified as safe.
• The limits should realistically reflect batch and stability data.
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012126
Setting limits – Organic impurities
Maximum daily dose
Qualification Threshold - The lower of:
% of API TDI
API < 2g 0.15% 1.0 mg
> 2g 0.05% -
Organic Impurities
An organic impurity above the applicable ICH qualification threshold needs to be qualified.
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 1 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely observed at 0.08%
• Should the impurity be specified and identified?
127
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 1 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely observed at 0.08%.
• Should the impurity be specified and identified?
• No, <0.10%
128
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 1 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely observed at 0.08%
• Should the impurity be specified and identified?
• No, <0.10%
• Qualified?
129
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 1 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely observed at 0.08%
• Should the impurity be specified and identified?
• No, <0.10%
• Qualified?
• No, <0.15%
130
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 3 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely observed at 0.23%
• Should the impurity be specified and identified?
131
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 3 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely observed at 0.23%
• Should the impurity be specified and identified?
• Yes, >0.10%
132
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 3 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely observed at 0.23%
• Should the impurity be specified and identified?
• Yes, >0.10%
• Qualified?
133
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 3 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely observed at 0.23%
• Should the impurity be specified and identified?
• Yes, >0.10%
• Qualified?
• Yes, >0.15%
134
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 4 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely reported <0.2%
• Should the impurity be qualified?
135
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• Drug 4 – ICH ID threshold 0.10%, Qual threshold 0.15%
• Impurity routinely reported <0.2%
• Should the impurity be qualified?
• It is impossible to tell. The applicant will be asked to represent data with sufficient accuracy. Otherwise, yes, it will need to be qualified.
136
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012137
• By comparison to a limit specified in the Ph.Int., Ph.Eur., or USP for a specific impurity. It could even be in a monograph for another substance.
• Through toxicological trials.
• A statement in a monograph of "any other impurity NMT 0.5%" can not be used as justification for an impurity limit, as it is not specific.
Impurity limits > the ICH qualification threshold can be qualified:
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
• By comparison to levels found in an innovator or prequalified FPP.
• By comparison to a limit previously approved in a prequalified FPP. This is a last resort.
138
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012139
• The limit for any unspecified impurity should be at the ICH identification threshold.
• The limit for total impurity content should reflect batch data.
• These concepts are applicable to synthetic APIs, but could be used on a case by case basis for semi-synthetic APIs.
Setting limits – Organic impurities
WHO API prequalification and APIMF procedure tutorialMumbai, September 2012
Further information
The PQ website is a good source of information, please read.
http://www.who.int/prequal/info_applicants/API_info_applicants.htm
AND, ALSO
Please email me (or visit) if you have any questions.
One email could save you a lot of time.